Trial Profile

A Phase 2, Randomized, Open Label, Pivotal Study to Evaluate the Efficacy and Safety of HQP1351 in CML CP Patients Who Are Resistant and/or Intolerant to First- and Second-Generation Tyrosine Kinase Inhibitors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olverembatinib (Primary) ; Dasatinib; Hydroxycarbamide; Imatinib; Interferon; Nilotinib; Omacetaxine mepesuccinate
Indications Chronic myeloid leukaemia
Focus Registrational; Therapeutic Use
Sponsors Ascentage Pharma

04 Nov 2025 Results presented in the Ascentage Pharma Media Release.
04 Nov 2025 According to an Ascentage Pharma media release, results from this study will be presented at the 2025 ASH meeting in poster presentation.
03 Mar 2025 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com